• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

PAHO secures significant price reductions for hepatitis C medicines

Home > News

PAHO secures significant price reductions for hepatitis C medicines

Man talking with a doctor
4 Oct 2019
  • English
    • English
    • Español
    • Português

Washington DC, USA

Update 25 October 2019: PAHO has since communicated a price range of US$96-126 for SOF/DAC, depending on volumes.

Man talking with a doctor

The Pan-American Health Organization (PAHO) has succeeded in reducing the price of expensive medicines that can cure people living with hepatitis C (HCV), according to an announcement made at its 57th Directing Council meeting. PAHO has negotiated prices of US$129 for 3 months of treatment from generic sources of sofosbuvir/daclatasvir. This significant move could enable national programmes to scale up diagnosis and treatment and eliminate HCV as a public health problem.

HCV affects about seven million people in the Americas, but the majority of those living with the disease are not diagnosed and have no access to treatment. Few countries have to date managed to secure broad access to affordable medicines.

“This new price achieved by PAHO could help change the scenario for the countries where patent barriers don’t prevent them from purchasing generic sources,” said Michel Lotrowska, Director of DNDi Latin America. “With prices ranging from $1,230 to $4,500, the affordability barrier remains considerable for countries where HCV medicines are under patent, unless they take steps to overcome regulatory or intellectual property barriers.”

DNDi supports PAHO’s decision to make these prices public, as transparency is an important factor in helping countries know about and obtain lower prices. DNDi calls on PAHO and its member states to continue to use all options to improve access to affordable treatments, including following the example of countries such as Malaysia, where the local authorities have issued a “government use” (compulsory) licence enabling access to generic versions of a patented medicine to treat the disease.

Photo credit: Vinicius Berger-DNDi

Policy advocacy Registration & access Hepatitis C

Read, watch, share

Loading...
Publications
2 Sep 2025

DNDi Brochure

News
28 Aug 2025

Luke Kanyang’areng becomes first Kenyan to receive Human Rights and Nursing Award

Doctor speaking with a woman and her child
Press releases
22 Aug 2025

DNDi receives Japan’s Hideyo Noguchi Africa Prize 2025 for its work to develop new treatments for neglected diseases in Africa 

Dr Luis Pizarro delivering his acceptance address at the Hideyo Noguchi Africa Prize ceremony on 22 August 2025
News
22 Aug 2025

Acceptance address, Dr Luis Pizarro – Fifth Hideyo Noguchi Africa Prize Ceremony

Statements
21 Aug 2025

DNDi’s briefing note for the 75th Session of the World Health Organization Regional Committee for Africa

News
12 Aug 2025

DNDi calls for nominations for private sector Board member 

News
8 Aug 2025

Statement from DNDi on Kenya’s elimination of rhodesiense sleeping sickness as a public health problem 

News
5 Aug 2025

ADB and DNDi sign MoU to advance healthcare cooperation on neglected diseases in Asia and the Pacific

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License